MoonLake Immunotherapeutics (MLTX) Long-Term Investments (2020 - 2022)
MoonLake Immunotherapeutics (MLTX) posted quarterly Long-Term Investments of $115.1 million for Q1 2022, up 12712721.99% year-over-year from N/an in Q1 2021, and little changed quarter-over-quarter from $115.0 million in Q4 2021.
MoonLake Immunotherapeutics (MLTX) Long-Term Investments (2020 - 2022) Analysis & Trends
MoonLake Immunotherapeutics' Long-Term Investments history runs 3 years deep, the most recent figure standing at $115.1 million for Q1 2022.
- In Q1 2022, Long-Term Investments rose 12712721.99% year-over-year to $115.1 million; the TTM figure through Mar 2022 stood at $115.1 million (up 12712721.99% YoY), while the FY2021 annual figure was $115.0 million, up 25173337.2% from the prior year.
- Long-Term Investments for Q1 2022 stood at $115.1 million, roughly flat from $115.0 million in the prior quarter.
- The five-year high for Long-Term Investments was $115.1 million in Q1 2022, with the low at $457.0 in Q4 2020.
- The 3-year median for Long-Term Investments is $115.0 million (2021), against an average of $76.7 million.
- The sharpest annual moves came in 2021 and 2022: Long-Term Investments soared 25173337.2% in 2021, then surged 12712721.99% in 2022.
- MoonLake Immunotherapeutics' Long-Term Investments stood at $457.0 in 2020, then jumped by 25173337.2% to $115.0 million in 2021, then increased by 0.01% to $115.1 million in 2022.
- Business Quant data shows MLTX's Long-Term Investments at $115.1 million in Q1 2022, $115.0 million in Q4 2021, and $115.0 million in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 372.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.17 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | MoonLake Immunotherapeutics | 1.40 Bn | 864.68 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | 115.05 Mn |
| Dec 31, 2021 | 115.04 Mn |
| Sep 30, 2021 | 115.04 Mn |
| Jun 30, 2021 | 115.04 Mn |
| Mar 31, 2021 | 905.00 |
| Dec 31, 2020 | 457.00 |